← Leaderboards
Gustavo Eduardo Velasquez
University Of California, San Francisco
$1,241,431
Attributed
$1,241,431
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $256.5K · FY2019–24$500K$375K$250K$125K$0
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$1,241,431 · 2
By mechanism
K08$984,927 · 1
R34$256,504 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of California, San Francisco
Same institution · by research overlap
- Moon S Chen$20,241,983
- Payam Nahid$19,473,523
- Adithya Cattamanchi$24,815,234
- Janice Y. Tsoh$9,696,129
- John Zapata Metcalfe$8,956,853
Others in their field
Other Emerging Leaders on “Treatment Protocols”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Kimberly Smith · Ppd Development Lp$115,671,664
- Beth Baseler · Leidos Biomedical Research, Inc.$73,306,144
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$62,228,229
- Susan Abushakra · Alzheon, Inc.$47,265,244
Research focus
Treatment ProtocolsInternationalRifampinTuberculosisRecommendationPharmaceutical PreparationsLinezolidRegimenSafetyAdverse EventCountryDoseAwardClinical TrialsDrug KineticsArthralgiaClinical ResearchClinical Decision-MakingDrug EvaluationDrug ExposureData SetDatabasesAntiretroviral TherapyConventional Therapy
Grant awards (7)
A Phase 2C Randomized, Controlled, Open-Label Trial of Novel Shortened Regimens for the Treatment of Isoniazid-Monoresistant TB (IMR-TB)$256,504
R34 · FY2024 · AI · contact PI
Safety and tolerability of new and repurposed drugs for MDR-TB treatment$197,640
K08 · FY2023 · AI · contact PI
Safety and tolerability of new and repurposed drugs for MDR-TB treatment$196,981
K08 · FY2022 · AI · contact PI
Safety and tolerability of new and repurposed drugs for MDR-TB treatment$99,890
K08 · FY2021 · AI · contact PI
Safety and tolerability of new and repurposed drugs for MDR-TB treatment$97,211
K08 · FY2021 · AI · contact PI
Safety and tolerability of new and repurposed drugs for MDR-TB treatment$196,727
K08 · FY2020 · AI · contact PI
Safety and tolerability of new and repurposed drugs for MDR-TB treatment$196,478
K08 · FY2019 · AI · contact PI